Search Filters

Search Results

Found 3 results

510(k) Data Aggregation

    K Number
    K173386
    Date Cleared
    2018-04-09

    (161 days)

    Product Code
    Regulation Number
    878.4460
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    This surgeon's glove is a device made of Flexylon intended to be worn by operating room personnel to protect a surgical wound from contamination. These Gloves are tested for use with Chemotherapy Drugs DO NOT USE with Carmustine or Thiotepa.

    Device Description

    This surgeon's glove is a device made of Flexylon.

    AI/ML Overview

    This document is a 510(k) premarket notification for Finessis Zero Flexylon Powder Free Sterile White Surgical Gloves, tested for use with chemotherapy drugs. It is a Class I device, regulated under 21 CFR 878.4460 (Surgeon's Glove), with product codes KGO and LZC.

    The study presented focuses specifically on the glove's resistance to breakthrough by various chemotherapy drugs, as tested according to ASTM D6978-05.

    Here's an analysis of the provided information, structured according to your request:

    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria are not explicitly stated in a general sense within the document, but the performance is presented as the breakthrough detection time for each chemotherapy drug. The implicit acceptance criterion for a glove "tested for use with chemotherapy drugs" is that it should demonstrate a reasonable and safe resistance to permeation by these cytotoxic agents. For most drugs, the goal is "No Breakthrough up to 240 min."

    Tested Chemotherapy Drug and Concentration per ASTM D6978-05Acceptance Criteria (Implicit)Reported Device Performance (Minimum Breakthrough Detection (Specimen 1/2/3) (Minutes))Meets/Does Not Meet (Relative to 240 min goal)
    Drugs with Breakthrough:> 240 min (ideal)
    1 Carmustine (BCNU), 3.3mg/ml (3,300 ppm)> 240 min (ideal, but a specific threshold for "safety" is not given)6.9 (9.0, 12.3, 6.9)Does Not Meet
    12 Thiotepa, 10.0 mg/ml (10,000 ppm)> 240 min (ideal, but a specific threshold for "safety" is not given)7.6 (9.2, 7.6, 10.0)Does Not Meet
    Drugs with No Breakthrough:No Breakthrough up to 240 min
    2 Cisplatin, 1.0 mg/ml (1,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    3 Cyclophosphamide (Cytoxan), 20 mg/ml (20,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    4 Dacarbazine (DTIC) 10.0 mg/ml (10,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    5 Doxorubicin Hydrochloride, 2.0mg/ml (2,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    6 Etoposide (Toposar), 20.0 mg/ml (20,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    7 Fluorouracil, 50.0 mg/ml (50,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    8 Ifosfamide, 50.0 mg/ml (50,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    9 Methotrexate, 25 mg/ml (25,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    10 Mitomycin C, 0.5 mg/ml (500 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    11 Paclitaxel (Taxol), 6.0 mg/ml (6,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    13 Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    14 Bleomycin, 15 mg/ml (15,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    15 Busulfan, 6 mg/ml (6,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    16 Carboplatin, 10 mg/ml (10,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    17 Cytarabine, 100 mg/ml (100,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    18 Daunorubicin, 5 mg/ml (5,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    19 Docetaxel, 10.0 mg/ml (10,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    20 Epirubicin, 2.0 mg/ml (2,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    21 Fludarabine, 25 mg/ml (25,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    22 Ganciclovir, 10 mg/ml (10,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    23 Gemcitabine (Gemzar), 38 mg/ml (38,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    24 Idarubicin, 1.0 mg/ml (1,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    25 Irinotecan, 20.0 mg/ml (20,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    26 Mechlorethamine HCI, 1.0 mg/ml (1,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    27 Melphalan, 5.0 mg/ml (5,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    28 Mitoxantrone, 2.0 mg/ml (2,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    29 Oxaliplatin, 2.0 mg/ml (2,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    30 Rituximab, 10 mg/ml (10,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    31 Trisenox, 0.1 mg/ml (100 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets
    32 Vinorelbine, 10 mg/ml (10,000 ppm)No Breakthrough up to 240 minNo Breakthrough up to 240 min.Meets

    Note: The FDA's overall determination of substantial equivalence for the device based on all presented information, including this performance data. The "Do Not Use" recommendation for Carmustine and Thiotepa directly addresses the drugs where breakthrough occurred rapidly.

    2. Sample Size Used for the Test Set and Data Provenance

    • Sample Size: For each chemotherapy drug, the test set involved 3 specimens of the glove, as indicated by "Specimen 1/2/3" in the "BREAKTHROUGH DETECTION (Specimen 1/2/3) (Minutes)" column.
    • Data Provenance: The document does not explicitly state the country of origin of the data. However, the testing was conducted per ASTM D6978-05, which is an American Society for Testing and Materials standard. The study seems to be a prospective evaluation, as new gloves were tested against specific chemicals to determine their performance.

    3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts

    This device is not an AI device or one that requires clinical expert interpretation for its core functionality. The "ground truth" here is the physical property of the glove's resistance to chemical permeation, which is measured objectively through a standardized laboratory test (ASTM D6978-05). Therefore:

    • Number of Experts: Not applicable in the context of expert human interpretation; the "ground truth" is established by the results of a standardized chemical permeation test.
    • Qualifications of Experts: Not applicable. The test relies on standardized methodology and instrumentation rather than expert opinion.

    4. Adjudication Method for the Test Set

    Not applicable. This is a scientific, objective laboratory test. The measurement of breakthrough time for each specimen is a direct outcome of the test procedure, not subject to human adjudication in the sense of reconciling differing opinions.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done

    No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic devices where human readers interpret images or data, and the goal is often to see how AI assistance improves reader performance. This document describes the chemical resistance of a surgical glove, which is a material property test.

    6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

    Yes, in a conceptual sense, a "standalone" performance evaluation was done. The device (the surgical glove) was tested without any human "in-the-loop" influencing its chemical resistance or the measurement of that resistance. The test itself measures the intrinsic property of the glove material.

    7. The Type of Ground Truth Used

    The ground truth used is objective physical measurement data obtained through a standardized laboratory test (ASTM D6978-05). Specifically, it measures the "breakthrough detection time" of various chemotherapy drugs through the glove material.

    8. The Sample Size for the Training Set

    Not applicable. This is not a machine learning or AI device that requires a "training set." The performance data is derived from direct physical testing of the glove material.

    9. How the Ground Truth for the Training Set was Established

    Not applicable, as there is no training set for this type of device and study.

    Ask a Question

    Ask a specific question about this device

    K Number
    K171987
    Date Cleared
    2017-10-20

    (109 days)

    Product Code
    Regulation Number
    878.4460
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    This surgeon's glove is a device made of Flexylon intended to be worn by operating room personnel to protect a surgical wound from contamination.

    Device Description

    Finessis Zero Flexylon Powder Free Sterile White Surgical Glove

    AI/ML Overview

    This document is an FDA 510(k) clearance letter for a surgical glove. It does not contain information about acceptance criteria or a study proving that a device meets acceptance criteria in the format requested. The document primarily focuses on the regulatory clearance of a medical device (surgical glove) and confirms its substantial equivalence to a predicate device.

    Therefore, I cannot extract the requested information regarding acceptance criteria, device performance, study details (sample size, data provenance, expert qualifications, adjudication method, MRMC study, standalone performance), or ground truth establishment.

    Ask a Question

    Ask a specific question about this device

    K Number
    K151607
    Date Cleared
    2015-11-16

    (154 days)

    Product Code
    Regulation Number
    878.4460
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    This surgeon's glove is a device made of Flexylon intended to be worn by operating room personnel to protect a surgical wound from contamination.

    Device Description

    FINESSIS ZERO Flexylon Powder Free Sterile White Surgical Glove. Flexylon; a styrene-ethylene/butylene-styrene (SEBS) material.

    AI/ML Overview

    The provided text is related to an FDA 510(k) clearance for a surgical glove. It describes the clearance of "FINESSIS ZERO Flexylon Powder Free Sterile White Surgical Glove" and states that it has been deemed substantially equivalent to legally marketed predicate devices.

    However, the document is a regulatory approval letter and an "Indications for Use" statement. It does not contain any information about acceptance criteria for device performance, or details of a study that proves the device meets those criteria.

    Therefore, I cannot provide the requested information from the given input. The document focuses on regulatory approval based on substantial equivalence, not on specific performance data or a study design.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1